Department of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Nephrology, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
J Cell Biochem. 2019 Jan;120(1):105-114. doi: 10.1002/jcb.27130. Epub 2018 Sep 14.
The correlation between lung cancer tumor markers and sex differences in lung cancer remains a clinical problem that is worthy of further study. This study investigated the significance of the combined detection of 17β-estrogen (E2) and tumor markers in the diagnosis and prognosis of lung cancer. A total of 174 patients, including 117 patients with non-small-cell lung cancer (NSCLC) and 57 patients with benign pulmonary lesions (BPL), were enrolled. An enzyme-linked immunosorbent assay was used to detect the expression of E2, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) in patients with NSCLC and BPL to analyze the correlation between E2 and CEA, NSE or CYFRA21-1 expression, and its correlation with clinicopathological features and prognosis. The expression of tumor markers was then examined in different lung cancer cells (A549, H1795, H460, and SK-MES-1). The expression of tumor markers was detected by a real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis. The expressions of p-p44/42 mitogen-activated protein kinase (MAPK) and phospho-AKT (p-AKT) were detected by Western blot analysis. The expression levels of E2, CEA, NSE, and CYFRA21-1 in patients with NSCLC were significantly higher than those in patients with BPL ( P < .05); E2 was positively correlated with tumor markers ( P < .01). Patients with a high expression of E2 and tumor markers showed a poor prognosis ( P < .05). RT-quantitative PCR and Western blot analysis showed that the expression levels of CEA, NSE, CYFRA21-1, p-p44/42 MAPK, and p-AKT in the E2 group were higher than those in the other groups ( P < .05). These studies indicate that the interaction of E2 and tumor markers can significantly improve the role of tumor markers in the diagnosis and prognosis of lung cancer.
肺癌肿瘤标志物与肺癌性别差异的相关性仍然是一个临床问题，值得进一步研究。本研究探讨了联合检测 17β-雌二醇（E2）和肿瘤标志物在肺癌诊断和预后中的意义。共纳入 174 例患者，包括 117 例非小细胞肺癌（NSCLC）患者和 57 例良性肺部病变（BPL）患者。采用酶联免疫吸附试验检测 NSCLC 和 BPL 患者 E2、癌胚抗原（CEA）、神经元特异性烯醇化酶（NSE）和细胞角蛋白 19 片段抗原 21-1（CYFRA21-1）的表达，分析 E2 与 CEA、NSE 或 CYFRA21-1 表达的相关性及其与临床病理特征和预后的相关性。然后在不同的肺癌细胞（A549、H1795、H460 和 SK-MES-1）中检测肿瘤标志物的表达。采用实时逆转录-聚合酶链反应（RT-PCR）和 Western blot 分析检测肿瘤标志物的表达。Western blot 分析检测 p-p44/42 丝裂原活化蛋白激酶（MAPK）和磷酸化 AKT（p-AKT）的表达。NSCLC 患者的 E2、CEA、NSE 和 CYFRA21-1 表达水平明显高于 BPL 患者（P<.05）；E2 与肿瘤标志物呈正相关（P<.01）。E2 和肿瘤标志物高表达的患者预后较差（P<.05）。RT-定量 PCR 和 Western blot 分析显示，E2 组的 CEA、NSE、CYFRA21-1、p-p44/42 MAPK 和 p-AKT 表达水平均高于其他组（P<.05）。这些研究表明，E2 和肿瘤标志物的相互作用可显著提高肿瘤标志物在肺癌诊断和预后中的作用。
